Cancer immunotherapy

Opportunities and challenges in the rapidly evolving clinical landscape

Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco M. Marincola

Research output: Contribution to journalReview ArticleOtherpeer-review

105 Citations (Scopus)

Abstract

Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.

Original languageEnglish
Pages (from-to)116-129
Number of pages14
JournalEuropean Journal of Cancer
Volume81
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Cancer immunotherapy
  • Cytotoxic T lymphocyte antigen-4 (CTLA-4)
  • Immune checkpoint blockade
  • Programmed death ligand-1 (PD-L1)
  • Programmed death-1 (PD-1)
  • Tumour immunity

Cite this

Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., ... Marincola, F. M. (2017). Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 81, 116-129. https://doi.org/10.1016/j.ejca.2017.01.035
Emens, Leisha A. ; Ascierto, Paolo A. ; Darcy, Phillip K. ; Demaria, Sandra ; Eggermont, Alexander M.M. ; Redmond, William L. ; Seliger, Barbara ; Marincola, Francesco M. / Cancer immunotherapy : Opportunities and challenges in the rapidly evolving clinical landscape. In: European Journal of Cancer. 2017 ; Vol. 81. pp. 116-129.
@article{c40c36c81c904234b174428b8d16e540,
title = "Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape",
abstract = "Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.",
keywords = "Cancer immunotherapy, Cytotoxic T lymphocyte antigen-4 (CTLA-4), Immune checkpoint blockade, Programmed death ligand-1 (PD-L1), Programmed death-1 (PD-1), Tumour immunity",
author = "Emens, {Leisha A.} and Ascierto, {Paolo A.} and Darcy, {Phillip K.} and Sandra Demaria and Eggermont, {Alexander M.M.} and Redmond, {William L.} and Barbara Seliger and Marincola, {Francesco M.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.ejca.2017.01.035",
language = "English",
volume = "81",
pages = "116--129",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier",

}

Emens, LA, Ascierto, PA, Darcy, PK, Demaria, S, Eggermont, AMM, Redmond, WL, Seliger, B & Marincola, FM 2017, 'Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape', European Journal of Cancer, vol. 81, pp. 116-129. https://doi.org/10.1016/j.ejca.2017.01.035

Cancer immunotherapy : Opportunities and challenges in the rapidly evolving clinical landscape. / Emens, Leisha A.; Ascierto, Paolo A.; Darcy, Phillip K.; Demaria, Sandra; Eggermont, Alexander M.M.; Redmond, William L.; Seliger, Barbara; Marincola, Francesco M.

In: European Journal of Cancer, Vol. 81, 01.08.2017, p. 116-129.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Cancer immunotherapy

T2 - Opportunities and challenges in the rapidly evolving clinical landscape

AU - Emens, Leisha A.

AU - Ascierto, Paolo A.

AU - Darcy, Phillip K.

AU - Demaria, Sandra

AU - Eggermont, Alexander M.M.

AU - Redmond, William L.

AU - Seliger, Barbara

AU - Marincola, Francesco M.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.

AB - Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.

KW - Cancer immunotherapy

KW - Cytotoxic T lymphocyte antigen-4 (CTLA-4)

KW - Immune checkpoint blockade

KW - Programmed death ligand-1 (PD-L1)

KW - Programmed death-1 (PD-1)

KW - Tumour immunity

UR - http://www.scopus.com/inward/record.url?scp=85020514166&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.01.035

DO - 10.1016/j.ejca.2017.01.035

M3 - Review Article

VL - 81

SP - 116

EP - 129

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -